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S U M M A R Y
Background: Hemophagocytosis during Q fever (QF) and Mediterranean spotted fever (MSF) is rare and
only a few cases have been reported. We aimed to investigate the characteristics, outcome, and
treatment of QF/MSF-associated hemophagocytosis.
Methods: We retrospectively reviewed all patients with a diagnosis of QF or MSF and suspected
hemophagocytic syndrome (HS), according to Henter’s criteria, between 2002 and 2011, and compared
the latter to patients without HS or with lymphoma-associated HS.
Results: Seventeen patients with HS (median age 42 years, range 5–68 years; ﬁve females (29%)) with QF
(n = 8) and MSF (n = 9) were included in this study. When comparing patients with QF- and MSF-
associated HS with patients without HS (n = 11), HS-associated signs (splenomegaly, ferritinemia,
hypertriglyceridemia, and cytopenia) were signiﬁcantly more frequent in patients with histological HS
(p < 0.05), along with a greater number of Henter’s criteria. Despite the presence of HS-associated signs,
treatment was similar in these two subgroups, including the time to recovery and the outcome. When
compared to lymphoma-associated HS (n = 10), the outcome in QF/MSF-associated HS was signiﬁcantly
different, with mortality in 70% of lymphoma patients versus none in QF- and MSF-associated HS
(p < 0.05).
Conclusion: Hemophagocytosis is a rare occurrence during the course of QF and MSF. The presence of
profound cytopenia is quite unusual in QF and MSF and should bring to mind the presence of associated
HS. Nevertheless, hemophagocytic syndrome is associated with a good outcome in this condition.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hemophagocytic syndrome (HS) is a rare life-threatening
condition characterized by fever, organomegaly, cytopenia, and
the presence of histological hemophagocytosis.1,2 HS is due to
uncontrolled macrophage activation leading to phagocytosis of
different hematopoietic cells and an overproduction of proin-
ﬂammatory cytokines. HS may be categorized into primary genetic
and secondary HS, which is associated with malignancy, autoim-
mune disease, drug hypersensitivity reactions, and/or infections.
The diagnosis of HS remains controversial; the Henter criteria and
Imashuku criteria have been elaborated for primary HS, and while
widely used, have yet to be evaluated in secondary HS.3* Corresponding author. Tel.: +33 1 48026666; fax: +33 1 48026396.
E-mail address: arsene.mekinian@jvr.aphp.fr (A. Mekinian).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.12.026HS has been associated with a large variety of viral, bacterial,
and parasitic pathogens, with Epstein–Barr virus (EBV) and
mycobacteria being the main infectious causative agents.4
Among infections causing HS, Q fever (QF) and Mediterranean
spotted fever (MSF), caused by Coxiella burnetii and Rickettsia
conorii, respectively, have rarely been described. QF manifesta-
tions are highly aspeciﬁc, mostly acute hepatitis or pneumonia
for the acute form and endocarditis for chronic QF. MSF,
transmitted by the brown dog tick Rhipicephalus sanguineus,
causes a febrile rash predominantly on the palms and soles, with
the occasional presence of a black spot, which corresponds to the
eschar of tick inoculation. The outcome and treatment of HS in
these two infections remain undetermined (Table 1).5–13 We
targeted MSF and QF because they are among the most frequent
infections caused by intracellular pathogens associated to HS.
The aim of the present study was to describe HS associated with
QF and MSF and to analyze the outcome and treatment of HS inses. Published by Elsevier Ltd. All rights reserved.
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M. Lecronier et al. / International Journal of Infectious Diseases 17 (2013) e629–e633e630these patients. Patients with QF- or MSF-associated HS were
compared to patients with lymphoma-associated HS, as well as
patients with QF or MSF but without HS. An exhaustive literature
review of HS associated with QS and MSF was also performed.
2. Patients and methods
2.1. Study patients
We retrospectively reviewed all patients with a diagnosis of QF
or MSF and suspected HS between 2002 and 2011 at four
university hospitals (Bondy, Avicenne, Pontoise, and Marseille).
HS was determined according to the presence of six of the eight
Henter’s criteria: (1) fever >38.5 8C for more than 7 days; (2)
splenomegaly; (3) bicytopenia (hemoglobin (Hb) <9 g/dl, plate-
lets <100  109/l, neutrophils <1  109/l); (4) ferritinemia
>500 mg/l or ﬁbrinogen <1.5 g/l; (5) triglyceridemia >3 mmol/
l; and (6) histological evidence of hemophagocytosis.14 Since
natural killer (NK) cell activity and soluble interleukin (IL)-2R
levels are not routinely performed, at least ﬁve of eight Henter’s
criteria were required to retain a diagnosis of HS. HS was also
analyzed according to the Imashuku score: (1) fever >7 days; (2)
bicytopenia (Hb <9 g/dl, platelets <100  109/l, white blood cell
count <2  109/l); (3) ferritinemia >1000 mg/l; (4) lactate
dehydrogenase >1000 IU/l; and (5) histological evidence of
hemophagocytosis.15
QF and MSF were diagnosed using serological data with paired
sera: two different standardized indirect immunoﬂuorescence
antibody tests (bioMe´rieux and Eurobio commercial kits) were
used, and cut-off titers were anti-phase II IgG 1:200 and anti-
phase II IgM 1:50 for the diagnosis of acute QF, and IgG 1:80 for
MSF. Anti-phase I IgG and IgM for the diagnosis of chronic QF were
negative in all QF patients. Two patients with QF had positive PCR
on parafﬁn-embedded hepatic biopsy.
The diagnosis of HS was ascertained by histological examina-
tion when available, while the presence of ﬁbrin ring granuloma
was analyzed from liver biopsy (Figure 1).
For each patient, data pertaining to medical history, laboratory
and histological data, and treatments were collected. The data for
each patient were systematically reviewed by two investigators
(ML and VP). HIV, cytomegalovirus, EBV, herpes simplex virus, and
parvovirus B19 virus serologies were also recorded when available.
None of the patients had a family history of HS, autoimmune
diseases, or neoplasia.
2.2. Control cases
Eleven patients with a diagnosis of QF and MSF without HS from
our hospitals between 2002 and 2011 were also retrospectively
analyzed. Ten patients with B lymphoma and associated HS were
also analyzed in order to compare the outcome of QF- and MSF-
associated HS.
2.3. Literature review
A bibliographic search was performed (1984 to January 2012),
by two investigators (ML and VP) using the MEDLINE database
(National Library of Medicine, Bethesda, MD, USA) with the
following keywords Q fever, Coxiella burnetii, Mediterranean
spotted fever, ﬁbrin ring granuloma, Rickettsia conorii, hemopha-
gocytic syndrome, histiocytic hemophagocytosis. All articles with
sufﬁcient data were included in the literature review. The
literature search yielded 13 citations; all were analyzed and nine
were included in the review (four cases were excluded because of
insufﬁcient data16–19).
Figure 1. Representative microphotographs of the liver biopsy in a patient with Q
fever and hemophagocytic syndrome: (A) ﬁbrin ring granuloma were focally
observed (black arrow); (B) throughout the liver biopsy, Ku¨pffer cells were
hyperplasic (arrowheads) and engulfed red blood cells (arrows).
Table 2
Comparison of patients with Q fever/Mediterranean spotted fever-associated hemophago
with lymphoma-associated hemophagocytic syndrome
Characteristics QF/MSF without HS
n = 11
Age (years) 60 (23–85) 
Females 4 (35%) 
Fever 10 (90%) 
Splenomegaly, clinical 0c
Hemoglobin (g/dl) 13 (10.7–14)c
Platelets (109/l) 253 (260–560)c
Aspartate aminotransferase (U/l) 50 (20–300) 
Alanine aminotransferase (U/l) 50 (20–512) 
C-reactive protein (mg/l) 55 (12–170)c
Ferritinemia (mg/l) 430 (200–780)c
Fibrinogen (g/l) 4 (3–7) 
Lactate dehydrogenase (U/l) 410 (250–630)c
Triglycerides (g/l) 1.5 (1–2)c
Henter’s criteria 1 (0–2)c
Serology cut-off 416 (160–1200) 
Intravenous immunoglobulins 0c
Corticosteroids 0c
Recovery (days) 7 (2–30)c
Death 0c
All values are medians with ranges, or numbers with frequencies. QF, Q fever; MSF, M
a p < 0.05 QF/MSF–HS vs. QF/MSF without HS.
b p < 0.05 QF/MSF–HS vs. lymphoma–HS.
c p < 0.05 QF/MSF without HS vs. lymphoma–HS.
M. Lecronier et al. / International Journal of Infectious Diseases 17 (2013) e629–e633 e6312.4. Statistical analysis
Data are expressed as medians with ranges for continuous
variables, and as frequencies with percentages for qualitative
variables. The Fisher’s exact test was used to compare qualitative
variables, while the non-parametric Mann–Whitney U-test or
Wilcoxon test was used for continuous variables, as appropriate.
Statistical analyses were carried out using GraphPad Prism version
5.1 (GraphPad Software, San Diego, 2007).
3. Results
3.1. All patients with QF/MSF and HS
Seventeen patients (median age 42 years, range 5–68 years; ﬁve
females (29%)) with QF (n = 8) and MSF (n = 9) were included in the
study. The general characteristics and laboratory data of these
patients are summarized in Table 1. Underlying immunodepres-
sion was present in two cases (diabetes mellitus and alcoholic
hepatopathy). An exposure factor was present in all cases (travel in
an epidemic area, contact with infected animals). At least one
cytopenia was present in 15 of 17 cases (88%), with anemia in 14
cases (82%), thrombocytopenia in 13 cases (76%), and neutropenia
in seven cases (41%) (Table 1). Hyperferritinemia was noted in 10
of 11 cases (91%), hypertriglyceridemia in eight of 13 cases (65%),
and hepatic cytolysis in 12 of 17 cases (71%).
QF was conﬁrmed in eight cases and MSF in eight cases, with
serological median titers of phase II IgG 1:590 for QF and IgG
1:1920 for MSF. HS was conﬁrmed with more than ﬁve of eight
Henter criteria in three of 17 cases (18%), with three or four criteria
in 13 cases (82%), and with four or ﬁve Imashuku criteria in eight of
17 cases (47%). Histological hemophagocytosis was present in 15 of
17 cases (88%), while histological analysis was not performed in
the two remaining cases. Histological hemophagocytosis was
conﬁrmed in all cases of patients with QF and in seven of nine cases
(78%) with MSF. Fibrin ring granulomas were present in three of
ﬁve cases of patients with QF on liver histology.20
Patient treatment consisted of doxycycline in all cases, in
association with ceftriaxone (n = 2; 13%), levoﬂoxacin (n = 3; 13%),
intravenous immunoglobulins (n = 2; 13%), hydroxychloroquinecytic syndrome with patients without hemophagocytic syndrome and with patients
QF/MSF with HS
n = 17
Lymphoma
n = 10
42 (11–68) 60 (33–89)
5 (29%) 2(20%)b
17 (100%) 9 (90%)
8 (47%)a 5 (55%)
10.3 (7–15)a 8.5 (6–12.7)b
87 (3–830)a 30 (8–45)b
173 (35–700)a 90 (31–388)b
123 (30–585)a 29 (11–109)b
200 (30–310)a 164 (56–425)
4406 (275–15 000)a 7400 (900–20 800)
2.2 (1.2–5.5)a 4.2 (1.3–7)
1074 (348–2301)a 1178 (430–5334)
3 (1.1–5)a 3.9 (1.3–6)
4 (2–6)a 4 (3–5)
1024 (160–5120) -
2 (12%) 10 (100%)b
1 (6%) 9 (90%)b
10 (2–15) 36 (12–64)b
0 7 (70%)b
editerranean spotted fever; HS, hemophagocytic syndrome.
M. Lecronier et al. / International Journal of Infectious Diseases 17 (2013) e629–e633e632(n = 1; 6%), and corticosteroids (n = 1; 6%). The median duration of
antibiotic treatment was 15 days (range 10–21 days). No deaths
were recorded and all patients recovered with a median delay of 10
days (range 2–15 days).
3.2. Comparison of QF- and MSF-associated HS patients with those
without HS and with those with lymphoma-associated HS
Eleven patients (median age 60 years, range 23–85 years; four
females (35%)) with QF (n = 6) and MSF (n = 5) without HS were
included (Table 2). In these patients, complaints were fever (n = 10/
11; 90%), cough (n = 3), headache (n = 4), arthromyalgias (n = 6),
nausea/vomiting (n = 1), and skin lesions (n = 5), however none
had splenomegaly. Acute-phase reactants (erythrocyte sedimen-
tation rate >40 mm/1st h and C-reactive protein (CRP) >10 mg/l)
were present in all cases, although none had cytopenia. Hyper-
ferritinemia was noted in three of 10 cases (30%), triglyceridemia
was normal in all cases, and hepatic cytolysis was present in four of
10 cases (40%). Patient treatment consisted of doxycycline in all
cases, in association with quinolones (n = 2; 18%) and hydroxy-
chloroquine (n = 2; 18%). The median duration of antibiotic
treatment was 21 days (range 14–90 days). No deaths were
reported and all patients recovered with a median delay of 7 days
(range 4–30 days).
A second control group with a diagnosis of B lymphoma
included 10 patients (median age 59.5 years, range 33–89 years;
two females (20%)) (Table 2). Eighty percent of patients had severe
cytopenia, with anemia in eight cases (81%), thrombocytopenia in
all cases, and neutropenia in three of 10 cases (30%). Hyperferri-
tinemia was noted in all cases, hypertriglyceridemia in four of eight
cases (50%), and hepatic cytolysis in six of 10 cases (60%). Patient
treatment consisted of intravenous immunoglobulins (n = 10;
100%), with corticosteroids (n = 9; 90%) and chemotherapy (n = 7
cases; 70%). The median duration of hospitalization was 36 days
(range 12–64 days) and seven of 10 (70%) patients died.
When comparing patients with QF- and MSF-associated HS
with patients without HS, HS-associated signs were signiﬁcantly
more frequent in patients with histological HS (p < 0.05), along
with an increased number of Henter’s criteria (Table 2). In
particular, whereas hemoglobin and platelet levels remained
normal in patients without HS, median levels were signiﬁcantly
lower in patients with associated HS. Conversely, despite the more
frequent presence of HS-associated signs, treatment was similar in
these two subgroups, as were time to recovery and outcome.
Similarly, HS-associated signs were signiﬁcantly more frequent in
patients with lymphoma than in patients without HS, although
associated immunosuppressive agents and deaths were signiﬁ-
cantly more important in lymphoma patients (Table 2).
When comparing patients with QF- and MSF-associated HS
with patients with lymphoma-associated HS, hemoglobin and
platelet levels were signiﬁcantly less important than in lymphoma
patients, whereas other HS-associated signs and Henter’s criteria
were similar (Table 2). In contrast, despite more frequent
associated corticosteroid and immunoglobulin treatment in
lymphoma patients, the outcome in these patients was dramatic
in comparison to patients with QF- and MSF-associated HS, with
deaths in 70% of cases versus none in QF- and MSF-associated HS
(p < 0.05)
4. Discussion
In the present study, we describe the association of HS with QF
and MSF, and demonstrate the good outcome of HS in these
patients. Even mild cytopenia (especially thrombocytopenia) can
be seen in these infections; in our study in patients with associated
HS, median levels of cytopenia were much lower and couldincrease the association of secondary HS. In contrast to malignan-
cy- and HIV-associated HS, no immunosuppressive treatment was
usually necessary in QF- or MSF-associated HS and a complete
recovery could be attained with antibiotic treatment in almost all
patients.
The diagnosis of HS can be challenging, and the presence of ﬁve
of eight Henter’s criteria, as well as of histological hemophago-
cytosis is usually required. Even though these criteria were
assessed only in children in primary HS, they remain widely used,
although studies in both secondary HS and in adult HS are still
lacking.15 Moreover, these criteria include NK cell activity and
soluble IL-2R levels, which are rarely determined in routine
practice. Similar to the cases reported in the literature, only a few
of our patients fulﬁlled the Henter criteria, although NK cell
activity and soluble IL-2R levels were not performed in our clinical
study. Nevertheless, the presence of HS is highly probable in our
patients, since HS signs were signiﬁcantly more frequent in
patients with suspected HS, and most of the patients also
presented histological hemophagocytosis. However, HS remains
otherwise largely underdiagnosed, and the use of Henter’s criteria,
which combine certain criteria not routinely performed in daily
practice, could make this diagnosis still more difﬁcult.
Mild cytopenia could occur in QF or MSF without HS. In our
patients with suspected HS, the number of cytopenias and their
median levels signiﬁcantly differed from patients without HS,
since their frequency and median levels were similar to
lymphoma-associated HS. Nevertheless, other diagnoses could
explain the presence of cytopenia in QF and MSF. Bone marrow
necrosis could also account for pancytopenia, and cases of
autoimmune cytopenia have been described. Spleen rupture,
although rare, could also complicate the outcome of these
infections. Nevertheless, all of these situations remain rare, and
the presence of other HS signs in our patients along with
histological hemophagocytosis argues for HS-associated cytope-
nia in these patients. Hence, compared to patients without HS, the
presence of cytopenia in patients with QF and MSF should warn of
the presence of underlying HS and therefore prompt the
investigation of other signs of HS.
The pathophysiology of acquired HS is not fully understood. An
inappropriate Th-1 response to intracellular pathogens and
deﬁciency in cytotoxicity of NK and T CD8 cells could result in
persistent activation of lymphocytes and histiocytes, leading to the
production of high levels of pro-inﬂammatory cytokines, upregu-
lation of adhesion molecules, and expansion of inﬂammatory
monocytes. Proliferation of cytotoxic cells associated with an
uncontrolled immune response could drive excessive macrophage
activation and induce HS, but data are lacking to deﬁnitely
conclude on the HS pathways in these infections.
The prognosis of HS is variable and depends on the underlying
disease, but generally remains poor.21 In patients with hemato-
logical disease and EBV-associated lymphoma, the prognosis is
even more dramatic, as illustrated here in patients with lympho-
ma-associated HS. Moreover, recovery generally requires the use of
speciﬁc treatments, such as corticosteroids or other immunosup-
pressive drugs.22 In the present study, even though HS-associated
signs and Henter’s criteria were similar in patients with lymphoma
HS and infectious HS, the outcome was nonetheless excellent in
QF- and MSF-associated HS, in most cases without additional
treatment other than antibiotics. Furthermore, while organome-
galy, cytopenia, CRP levels, and other HS signs were more
important in patients with HS in comparison to QF and MSF
patients without HS, treatment, outcome, and recovery delays
were similar in these patients, and thus argue against the need for
any HS-speciﬁc treatment in patients with QF- and MSF-associated
HS. In our study, additional treatment was used in two patients
(immunoglobulins in two cases, with associated steroids in one of
M. Lecronier et al. / International Journal of Infectious Diseases 17 (2013) e629–e633 e633them), and the need for treatment other than antibiotics in some
selected patients could not be excluded.
Limitations of the present study include the small number of
patients as well as its retrospective design. Most of the patients did
not fulﬁll Henter’s HS criteria, although the comparison with a
control group without HS highlighted the high frequency of HS-
associated signs, thus justifying the diagnosis of HS. The absence of
NK cell activity and soluble IL-2R levels could largely explain the
absence of Henter’s criteria in these patients, and is counter-
balanced by the presence of histological HS in most of these
individuals.
In conclusion, hemophagocytosis is a rare occurrence during
the course of Q fever and Mediterranean spotted fever. The
presence of profound cytopenia should bring to mind the possible
presence of associated HS, but HS seems to be associated with a
good outcome in this condition.
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